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Abstract
Background: Neural stem cells (NSCs) display tissue trophic and immune modulatory therapeutic activities after
transplantation in central nervous system disorders. The intercellular interplay between stem cells and target
immune cells is increased in NSCs exposed to inflammatory cues. Here, we hypothesize that inflammatory cytokine
signalling leads to metabolic reprogramming of NSCs regulating some of their immune modulatory effects.
Methods: NSC lines were prepared from the subventricular zone (SVZ) of 7–12-week-old mice. Whole secretome-
based screening and analysis of intracellular small metabolites was performed in NSCs exposed to cocktails of either
Th1-like (IFN-γ, 500 U/ml; TNF-α, 200 U/ml; IL-1β, 100 U/ml) or Th2-like (IL-4, IL-5 and IL-13; 10 ng/ml) inflammatory
cytokines for 16 h in vitro. Isotopologues distribution of arginine and downstream metabolites was assessed by
liquid chromatography/mass spectrometry in NSCs incubated with U-13C6 L-arginine in the presence or absence of
Th1 or Th2 cocktails (Th1 NSCs or Th2 NSCs). The expression of arginase I and II was investigated in vitro in Th1
NSCs and Th2 NSCs and in vivo in the SVZ of mice with experimental autoimmune encephalomyelitis, as
prototypical model of Th1 cell-driven brain inflammatory disease. The effects of the inflammatory cytokine
signalling were studied in NSC-lymph node cells (LNC) co-cultures by flow cytometry-based analysis of cell
proliferation following pan-arginase inhibition with Nω-hydroxy-nor-arginine (nor-NOHA).
Results: Cytokine-primed NSCs showed significantly higher anti-proliferative effect in co-cultures vs. control NSCs.
Metabolomic analysis of intracellular metabolites revealed alteration of arginine metabolism and increased
extracellular arginase I activity in cytokine-primed NSCs. Arginase inhibition by nor-NOHA partly rescued the anti-
proliferative effects of cytokine-primed NSCs.
Conclusions: Our work underlines the use of metabolic profiling as hypothesis-generating tools that helps
unravelling how stem cell-mediated mechanisms of tissue restoration become affected by local inflammatory
responses. Among different therapeutic candidates, we identify arginase signalling as novel metabolic determinant
of the NSC-to-immune system communication.
Keywords: Metabolomics, Neural stem cells, Immune modulation, Lymph node cells, Arginase I
Abbreviations: BSTFA, Bistrimethyl-silyl-triflouroacetamide; CFSE, 5-(and-6)-carboxyfluorescein diacetate succinimidyl
ester; CGM, Complete growth medium; DAPI, 4,6-diamidino-2-phenylindole; DCs, Dendritic cells; dpi, Days post
immunization; EAE, Experimental autoimmune encephalomyelitis; EDTA, Ethylenediaminetetraacetic acid;
(Continued on next page)
* Correspondence: drago.denise@hsr.it; spp24@cam.ac.uk
1CNS Repair Unit, Institute of Experimental Neurology (INSPE), Division of
Neurosciences, San Raffaele Scientific Institute, 20132 Milan, Italy
7Department of Clinical Neurosciences, Wellcome Trust–Medical Research
Council Stem Cell Institute and National Institute for Health Research
Biomedical Research Centre, University of Cambridge, Hills Road, CB2 0HA
Cambridge, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Drago et al. Journal of Neuroinflammation  (2016) 13:232 
DOI 10.1186/s12974-016-0667-7
(Continued from previous page)
EdU, 5-ethynyl-2′deoxyuridine; EGF, Epidermal growth factor; ESI, Electrospray ionization; FGF-2, Fibroblast growth
factor; FT-ICR, Fourier transform ion cyclotron resonance; GC/MS, Gas chromatography/mass spectrometry; LC/
MS, Liquid chromatography/mass spectrometry; LIT, Linear ion trap; LNC, Lymph node cells; MetPA, Metabolic
pathway analysis; MOG, Myelin oligodendrocyte glycoprotein; MPCs, Myeloid precursor cells; nor-NOHA, Nω-
hydroxy-nor-arginine; NSCs, Neural stem cells; OCT, Optimal cutting temperature; PBS, Phosphate-buffered saline;
PFA, Paraformaldehyde; PLS-DA, Partial least squares discriminant analysis; PTEN, Phosphatase and tensin homolog;
QA, Quality assurance; QC, Quality control; ROI, Region of interest; SVZ, Subventricular zone; TBST, Tris-buffered
saline/Tween; TLR, Toll-like receptor; WB, Western blotting
Background
Compelling evidence is available that transplanted stem
cells promote significant clinico-pathological recovery in
several preclinical models of neurological disorders such
as multiple sclerosis, cerebral stroke and spinal cord
injury [1–4].
Remarkable neuroprotective and immune modulatory
capacities have been identified for neural stem cells
(NSCs) that may result from consistent mechanisms of
intercellular interplay with target host cells and may
predominantly account for the therapeutic effects of
NSC grafts [2, 5–9]. The putative mechanisms that
sustain both repair capabilities, as well as long-term
functional integration of NSCs upon transplantation, are
yet to be fully understood.
Rodent NSCs inhibit the activation and proliferation
of antigen-specific and antigen non-specific Th1 and
Th17 cells in vitro, as well as promote T cell apoptosis
[6, 9–11]. Human NSCs suppress the proliferation and
alter the profile of cytokine secretion of xenogeneic
antigen-specific and allogeneic mitogen-activated T cells
[12, 13]. Compared to rodent NSCs, human NSCs have
a lower cytotoxicity towards T cells but a higher cytotox-
icity towards monocyte/macrophages in vitro [14].
Human NSCs also hinder the differentiation of myeloid
precursor cells (MPCs) into immature dendritic cells
(DCs), and the maturation of immature DCs to func-
tional antigen-presenting cells [13]. Recent studies have
also shed new light on the understanding of mechanisms
of transcellular information exchange and demonstrated
that cytokine-regulated exosome signalling is an import-
ant pathway by which NSCs exploit some of their
protective capacities [15]. In parallel to these functional
studies, the investigation of the stem cell secretome has
gained increasing attention in recent years because of its
multiple implications for the potential reparative,
restorative, or regenerative applications of stem cell
medicines [16–19]. Paracrine signalling mediated by stem
cells plays an essential role in the reparative process
observed after stem cells transplantation, with stem cells
secreting growth factors, chemokines and cytokines, both
constitutively as well as in response to priming with pro-
inflammatory molecules [17, 18, 20–23].
Thus, the concept that stem cells solely act as directly
repairing cells is now being revisited and enriched with
the emerging view that stem cells secrete certain regen-
erative factors in response to environmental stimuli,
which include cytokines, growth factors, morphogens
and toll-like receptor (TLR) ligands [16, 24]. Hypoxic
preconditioning, exposure to inflammatory cytokines or
mechanical and shear stress conditioning (e.g. growing
cells in 3D spheres or scaffolds) have all been shown to
promote the release of different potential therapeutic
small molecules [24, 25].
The ability of stem cells to secrete neuroprotective
and immune modulatory factors indicates that there is
still a lot to learn about functional stem cell plasticity,
especially when the regulation of host responses is
enhanced after licensing or priming with inflammatory
cytokines such as for NSCs [21].
Metabolomics is a promising complementary approach
to explore the functional stem cell response to cellular
signalling and is defined as the metabolic complement of
functional genomics. Metabolomics enables the systematic
analysis of small metabolites involved in biochemical reac-
tions, revealing connections between different pathways
that operate within living cells [26–30]. The identity, con-
centration and fluxes of metabolites are the final product
of interactions between gene expression, protein expres-
sion and the cellular environment. Thus, metabolomics
amplifies changes both in the proteome and the genome
and represents a more accurate approximation to the
phenotype of an organism in health and disease [31, 32].
We exploited metabolomics to investigate whether
cytokine signalling leads to metabolic reprogramming of
NSCs driving some of their immune modulatory effects.
To this aim, we sought to measure small molecules
from undifferentiated mouse NSCs and anticipated that
these compounds were altered in NSCs primed with
inflammatory cytokines. Whole secretome-based screen-
ing and analysis of intracellular small metabolites were
performed in NSCs after exposure to a cocktail of Th1-
like or Th2-like inflammatory cytokines as in vitro
system mimicking the putative inflammatory niche that
has been described to induce an immune modulatory
phenotype in stem cells in vivo [3].
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Our high-throughput omic approach defined the arginine
metabolism to be mostly altered in Th1 NSCs. In parallel,
we found that NSCs constitutively expressed both intracellu-
lar arginase II and extracellular arginase I, while arginase in-
hibition by Nω-hydroxy-nor-arginine (nor-NOHA) blocked
some of the immune modulatory effects of Th1 NSCs.
Our work underlines the use of the NSC metabolome
as a hypothesis-generating tool for the identification of
candidate biomarkers that will predict or measure
pharmacological efficacy or toxic responses. It also
identifies arginase signalling as a novel metabolic deter-
minant of the NSC-to-immune system communication




NSCs lines were prepared from the subventricular zone
(SVZ) of 7–12-week-old female SJL mice (18–20 gr.
Charles River). NSCs were grown in a serum-free basal
medium, NeuroCult basal medium plus mouse NeuroCult
proliferation supplements (Complete Growth Medium,
CGM; Stem Cell Technologies) supplemented with 2 μg/
ml heparin (Sigma-Aldrich), 20 ng/ml purified human
recombinant epidermal growth factor (EGF; Provitro) and
10 ng/ml human recombinant fibroblast growth factor
(FGF)-2 (Provitro) [9]. At time of passaging (every 3–5
days), neurospheres were dissociated by enzymatic diges-
tion with Accumax (Sigma) at 37 °C for 15 min, the num-
ber of viable cells determined by trypan blue exclusion and
viable cells re-plated at 8000 cells/cm2 (1.3 × 106 cells with
15-ml media in T162 flask) [33]. NSCs at passage number
≤15 were used in all experiments.
Th1 and Th2 cytokine priming
NSCs were plated in CGM with or without either Th1-
like (200 U/ml recombinant mouse TNF-α, Pepro Tech
Inc.; 500 U/ml recombinant mouse IFN-γ, Pepro Tech
Inc; 100 U/ml recombinant mouse IL-1β, Pepro Tech Inc)
or Th2-like (10 ng/ml recombinant murine IL-4, R&D;
10 ng/ml recombinant mouse IL-5, R&D; 10 ng/ml
recombinant mouse IL-13, R&D) cytokine cocktails for
16 h in vitro [33]. At the end of the conditioning, NSCs
were washed three times with phosphate-buffered saline
(PBS) to remove cytokine contamination before cell har-
vesting. Finally, NSCs and NSC-conditioned media were
processed according to the analysis to be performed.
Metabolomic analysis by liquid chromatography/mass
spectrometry (LC/MS) and gas chromatography/mass
spectrometry (GC/MS)
Sample preparation
NSCs were plated at 348,000 cells/ml (5.2 × 106 cells with
15-ml media in T162 flask) in CGM added with either
Th1-like or Th2-like cytokine cocktails as above. Basal,
Th1, and Th2 NSCs were harvested (107 cells per sample),
and the supernatants immediately collected to be analysed
by using Metabolon platform service. Five biological repli-
cates of NSCs pellets were washed twice with PBS and
then snap-frozen on dry ice and stored at −80 °C until
shipment to Metabolon. The sample preparation process
was carried out using the automated MicroLab STAR®
system from Hamilton Company. Recovery standards
were added prior to the first step in the extraction process
for quality control (QC) purposes. Sample preparation
was conducted using a proprietary series of organic and
aqueous extractions to remove the protein fraction while
allowing maximum recovery of small molecules. The
resulting extract was divided into two fractions: one for
analysis by LC and one for analysis by GC. The samples
were placed briefly on a TurboVap® (Zymark) to remove
the organic solvent. Each sample was then frozen and
dried under vacuum. The samples were then prepared for
the appropriate instrument, either LC/MS or GC/MS.
Quality assurance (QA)/quality control (QC)
For quality assurance QA/QC purposes, additional
samples were included with each day’s analysis. These
samples included a well-characterized pool of human
plasma, a pool of a small aliquot of each experimental
sample, an ultra-pure water process blank and an aliquot
of solvents used in extraction to segregate contamination
sources in the extraction. Furthermore, a selection of
QC compounds was added to every sample, including
those under test. These compounds were chosen
carefully so as not to interfere with the measurement of
the endogenous compounds.
GC/MS
The samples destined for GC/MS analysis were re-dried
under vacuum desiccation for a minimum of 24 h prior to
being derived under dried nitrogen using bistrimethyl-
silyl-triflouroacetamide (BSTFA). The GC column was
5 % phenyl and the temperature ramp was from 40 to
300 °C in a 16-min period. The samples were analysed on
a Thermo-Finnigan Trace DSQ fast-scanning single-
quadrupole mass spectrometer using electron impact
ionization. The instrument was tuned and calibrated for
mass resolution and mass accuracy on a daily basis. The
information output from the raw data files was automatic-
ally extracted as discussed below.
Accurate mass determination and MS/MS fragmentation
(LC/MS), (LC/MS/MS)
The LC/MS portion of the platform was based on a
Waters ACQUITY UPLC and a Thermo-Finnigan LTQ-
FT mass spectrometer, which had a linear ion trap (LIT)
front end and a Fourier transform ion cyclotron resonance
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(FT-ICR) mass spectrometer back end. For ions with
counts greater than two million, an accurate mass meas-
urement could be performed. Accurate mass measure-
ments could be made on the parent ion as well as
fragments. The typical mass error was less than 5 ppm.
Ions with less than two million counts require a greater
amount of effort to characterize. Fragmentation spectra
(MS/MS) were typically generated in a data-dependent
manner, but if necessary, targeted MS/MS could be
employed, such as in the case of lower level signals.
Western blotting
NSCs were plated at 348,000 cells/ml, collected after
16 h of incubation in CGM without or with Th1 or Th2
cytokines and washed with PBS. Conditioned media
were collected and immediately frozen at −80 °C before
the protein quantification. Protein quantification was
performed using Direct Detect Spectrometer (Millipore).
One hundred microgram of total protein for NSC-
conditioned media were separated by SDS-PAGE using
4–12 % precast NuPAGE Bis-Tris gels (1.5-mm thick-
ness) under reducing (Reducing Buffer, 10×) conditions
and MES running buffer and then transferred onto
nitrocellulose membranes (0.45-μm pore size, Hybond
ECL) using XCell II Blot Module and NuPAGE transfer
buffer (all from Invitrogen). Molecular weight marker:
SeeBluePlus2PrestainedStandard (Invitrogen). For immu-
noblot analysis, the membranes were blocked for 1 h at
room temperature with Tris-buffered saline/Tween
(TBST; 10 mM Tris-HCl, 150 mM NaCl, 0.1 % Tween 20
pH 7.6) containing 5 % nonfat dry milk and then incu-
bated overnight at 4 °C with rabbit anti-arginase I (H-52,
Santa Cruz Biotech) or anti-arginase II antibody (H-64,
Santa Cruz Biotech) by using antibody dilution 1:200.
Mouse liver (sc-2256, Santa Cruz) and rat kidney (sc-
2394, Santa Cruz Biotech) extracts were used as positive
control for arginase I and arginase II, respectively. After
washing with TBST, the nitrocellulose membranes were
incubated with the appropriate donkey anti rabbit IgG
HRP antibody (Amersham NA9340V; dilution used:
1:3000) for 1 h at room temperature. Immunoreactivity
was revealed by using an ECL detection kit (Pierce).
Measurement of 13C-labelled metabolites by LC/MS
1 ×106 cells were plated in T25 flasks and cultured in
CGM supplemented with U-13C6 L-arginine (Cambridge
Isotopes Laboratories) for 2 h and 16 h in the absence
and in the presence of Th1 and Th2 cytokines cocktails.
The cells were then harvested, washed with PBS (2 ×
5 min), and lysed for 15 min at 4 °C under agitation with
1 ml of 50 % methanol and 30 % acetonitrile in water
kept in dry ice/methanol bath (−80 °C). The insoluble
material was pelleted in a cooled centrifuge at 14,000g
for 10 min at 4 °C and the supernatant were collected
for LC-MS analysis. XBridge Amide column (3.5 μm,
150 × 2.1 mm) was used for LC separation and the
detection of metabolites was performed using a Thermo
Scientific Q-Exactive high-resolution mass spectrometer
with electrospray (ESI) ionization, examining metabolites
in both positive and negative ion modes, over the mass
range of 75–1000 m/z. The mobile phase for elution was
a gradient established between water acidified with 0.1 %
formic acid (A) and acetonitrile acidified with 0.1 %
formic acid (B) at a flow rate of 200 μl/min. The gradi-
ent used was preceded by an isocratic step at 20 % A/
80 % B. This step was followed by a linear decrease of B
at 20 % in 25 min and re-equilibration at 20 % A/ 80 %
B for 11 min. The injected volume was 5 μl.
Urea cycle colorimetric assay
1.74 × 106 cells (cellular density 348,000 cells/ml) were
seeded onto T25 flask (5 ml medium) in the absence or
in the presence of either Th1 or Th2 cytokines cocktails.
NSCs at different experimental conditions were homoge-
nized in 100 μl Assay Buffer (Urea Assay Colorimetric
Kit, Biovision), centrifuged at 15,000g for 10 min to
remove insoluble materials. Fifteen-microliter samples
were directly added to a 96-well plate for the urea deter-
mination according to the manufacturer’s instructions.
Arginase enzymatic activity
The enzymatic activity of arginase within NSCs (with or
without Th1 or Th2 cytokines cocktails) was determined
by arginase activity colorimetric assay kit (BioVision).
Briefly, 1 × 106 cells at the same cellular density used for
the metabolomic studies (348,000 cells/ml) were dis-
solved with 100 μl ice-cold arginase buffer and centri-
fuged at 10,000g for 5 min. The supernatants were
collected, and 40 μl were used to perform the assay for
each samples.
NSC/lymph node cell co-culture
Axillary, brachial, cervical, inguinal, and mesenteric lymph
nodes were surgically excised from SJL mice and reduced
to single cell suspension by mechanical disruption.
In selected experiments, CD4+ T cells were purified by
negative selection using anti-CD8 (clone KT1.5) and anti-
I-Ab-d/I-E (clone B21-22) rat Abs and sheep anti-rat-
coated magnetic beads (Dynal Biotech, UK) to a purity of
95 %. Purified CD4 lymphocytes or unfractionated lymph
node cells (LNC) were seeded in 96-well plates (1 × 105
per well) in a final volume of 200 μl of CGM and were
stimulated with anti-mouse-CD3/CD28 beads (Dynabeads
mouse T-activator CD3/CD28, Invitrogen) at a ratio of 1:1
or left untreated. NSCs were pre-conditioned for 16 h
with Th1 or Th2 cytokines cocktails at 348,000 cells/ml
and then co-cultured with LNCs (NSC/LNC ratio 1:2) in
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the same well. NSCs were washed three times with PBS to
avoid any cytokine carry-over in the co-culture system.
In selected experiments, LNCs were labelled with the
vital dye, 5-(and-6)-carboxyfluorescein diacetate succini-
midyl ester (CFSE; Molecular Probes, Invitrogen), final
concentration of 1 μmol/L. Briefly, the cells were washed
twice with PBS and suspended at 20 × 106/ml in PBS. An
equal volume of CFSE at 2 μmol/L was then added.
After 8-min incubation under gentle shaking at room
temperature, an equal volume of FCS was added to
quench the reaction. LNCs were then washed twice in
RPMI with 10 % FCS and plated with NSCs in co-
cultures for 48 and 72 h, as above. LNCs were surface
stained with rat anti-mouse CD4 Pacific Blue conjugated
(clone RM4-5, BD Pharmingen) and CD44PerCP-Cy5.5
(BioLegend). The nuclear counterstain and dead cell in-
dicator TO-PRO3 Iodide (Molecular Probes) was added
before the flow cytometry acquisition. In a parallel co-
culture experiment, the cells were labelled for the last
5 h of a 72-h-long culture with 10 μM 5-ethynyl-2′deox-
yuridine (EdU). EdU-Click iT Flow Cytometry Assay
(Alexa 647, Invitrogen, Molecular Probes) was used to
detect EdU incorporation according to the manufac-
turer’s instructions (reaction volumes were adjusted to
50 μl). LNCs were surface stained with rat anti-mouse
CD4 Pacific Blue conjugated (clone RM4-5) and
CD44PerCP-Cy5.5.
Nω-hydroxy-L-arginine (nor-NOHA; 30 μM) was added
to cultures to inhibit arginase activity. Flow cytometry was
performed with FACSCalibur (BD Biosciences), and a
minimum of 15,000 events were acquired. Analysis of
FACS data was performed using the FlowJo_V10 software.
Arginase I and II expression on NSCs in vitro
Analysis of basal and cytokine-induced expression and
localization (cytosol vs. mitochondria) of arginase I and II
was done on mouse NSCs transduced with a 3rd
generation Mito-DsRed lentiviral vector. NSCs were plated
in CGM (laminin 1:100) at a density of 80,000 cells/cm2.
After 12 h, the cells were treated for additional 16 h in vitro
with Th1 or Th2 cytokine cocktails as above. Untreated
NSCs were used as controls. NSCs were fixed with parafor-
maldehyde (PFA) 4 % and then stained using a chicken
anti-nestin (1:500; Abcam) and a goat anti-arginase I
(1:100; Santa Cruz) or a rabbit anti-arginase II (1:100; Santa
Cruz) primary antibodies. Appropriate Alexa Fluor conju-
gated secondary antibodies were then used. Nuclei were
counterstained with 4, 6-diamidino-2-phenylindole (DAPI).
For the assessment of arginase I and II expression,
immunofluorescent staining were evaluated adopting a
CCD camera/fluorescent microscope; n = 5 equally distrib-
uted regions of interest (ROIs) were chosen and acquired
via ×20 objective lens for analysis (n = 4 cover slides were
used for each group). Fluorescence intensity was calculated
with ImageJ Software (NIH) and normalized on the num-
ber of DAPI+ cells/ROI. Data were expressed as arginase I
or II mean normalized intensities over micron2 ± SEM.
Arginase I and II expression on NSCs in vivo
Ex vivo histopathological fluorescent images of ArgI/ArgII
expression at level of SVZ were obtained from 4–8-week-
old C57BL/6 female mice with myelin oligodendrocyte
glycoprotein (MOG) peptide 35–55 induced experimental
autoimmune encephalomyelitis (EAE) at 25 and 50 days
post immunization (dpi), as described [33]. Strain-, age-,
sex- and weight-matched healthy mice were used as con-
trols. The mice were transcardially perfused with saline
EDTA and 4 % paraformaldehyde. Brains were removed
and post-fixed in PFA 4 % for 24 h at 4 °C and then
washed with PBS. The brains were cryoprotected with
30 % sucrose (Sigma) and then embedded in optimal
cutting temperature (OCT) Tissue Tek compound (EM
sciences) for freezing. Twenty five-micrometer-thick
coronal brain sections were cut and collected onto Super-
frostPlus slides (Menzel-Glaser, Thermo Fisher Scientific)
and processed for histopathology. The following primary
antibodies were used: goat anti-arginase I (1:100 Santa
Cruz), rabbit anti-arginase II (1:100 Santa Cruz), chicken
anti-nestin (1:500 Abcam) and a rat anti-CD45 (BD).
Appropriate Alexa Fluor-conjugated secondary antibodies
were used. Nuclei were counterstained with DAPI. Con-
focal microscopy images of SVZ healthy controls and
MOG-induced EAE mice were acquired at ×40 and ×63.
Statistical analysis
Statistically significant differences between experimental
groups were determined by Kruskal-Wallis followed by un-
paired two-tailed t test (for comparisons between groups).
*/°/^p ≤ 0.05; **/°°p ≤ 0.01; ***p ≤ 0.001 and n.s. = not signifi-
cant. Statistical analyses were performed using Prism
software (v6.0f, GraphPad Software, San Diego, CA).
Results
In vitro NSCs priming with inflammatory cytokines
potentiates their anti-proliferative effect on T cells
Priming with environmental stimuli that include cyto-
kines, growth factors, morphogens and toll-like receptor
(TLR) ligands modulates several stem cell functions [16,
34]. Here, we asked whether exposing NSCs to inflam-
matory cytokines, that are known to play a central role
in triggering and perpetuating chronic inflammation,
induces a licensing switch in their intrinsic immune
regulatory functions [35].
To evaluate the effects of NSCs on acute T cell responses,
we measured CD3/CD28-induced lymph node cell (LNC)
proliferation by flow cytometry using a carboxyfluorescein
diacetate succinimidyl ester (CFSE) dilution assay at both
48 and 72 h in vitro. These time points were selected based
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on previous data on proliferation and activation of rodent
LNCs in vitro [36]. LNCs were also stained with anti-CD44
antibodies to detect their activation. NSCs were first primed
for 16 h in vitro with a Th1-like cytokine cocktail composed
of IFN-γ, TNF-α and IL-1β or a Th2-like cytokine cocktail
composed of IL-4, IL-5 and IL-13 [33], and then tested for
their immune modulatory activity in same well co-cultures
with LNCs (Th1 NSC/LNC and Th2 NSC/LNC, respect-
ively). Co-cultures of basal (e.g. not exposed to cytokines)
NSCs and LNCs (NSC/LNC) or LNC preparations only
(LNC) were used as controls.
By 48 h, significantly higher proportions of CD4+ T cells
started to proliferate (CSFEdim) in NSC/LNC [43.7 %
(±4.2)], Th1 NSC/LNC [48.2 % (±1.5)] and Th2 NSC/LNC
[39.2 % (±1.1)] vs. LNC [2.64 % (±0.18); p ≤ 0.0001] (Fig. 1a,
b). By 72 h, the fraction of CFSEdim CD4+ T cells further in-
creased in all conditions, still being slightly more repre-
sented in NSC/LNC [83.9 % (±0.9)], Th1 NSC/LNC
[86.8 % (±1.7)] and Th2 NSC/LNC [87.8 % (±0.1)], vs. LNC
[77.3 % (±2.72); p ≤ 0.05 and p ≤ 0.01] (Fig. 1a, b). Neverthe-
less, we noticed a significantly higher proportion of CFSE-
dim CD4+ T cells expressing low levels of the activation
marker CD44 (CFSEdimCD44lowCD4+) within NSC/LNC,
Th1 NSC/LNC and Th2 NSC/LNC at both 48 and 72 h
[p ≤ 0.001 vs. LNC] (Fig. 1a, c). Comparable results were
obtained when NSCs were co-cultured with purified CD4+
T cells for 72 h in vitro (Additional file 1: Figure S1), thus
suggesting a direct effect of NSCs on CD4+ T cells.
Significantly higher proportions of CSFEdimCD44high
CD4+ T cells were also observed by 48 h in NSC/LNC
[36.8 % (±3.3)], Th1 NSC/LNC [39.3 % (±1.6)], and Th2
NSC/LNC [31.4 % (±0.8)] compared to LNC [1.6 % (±0.1);
p ≤ 0.0001]. By contrast, no differences in the proportion
of CD4+CSFEdimCD44high T cells were observed by 72 h in
any of the conditions tested (Fig. 1a, d).
LNCs in co-cultures at 72 h also showed a higher CFSE
content (CFSEhigh) vs. control LNC (Fig. 1e). This CFSEhigh
late LNC behaviour did not account for any significant
differences in the proportion of TO-PRO3+ apoptotic CD4
+ T cells; yet, it was associated to significant 4–8-fold higher
survival of LNCs in co-cultures [p ≤ 0.01 and p ≤ 0.001] vs.
control LNCs (Additional file 2: Figure S2).
We therefore reasoned that these results might suggest
that only in the presence of NSCs, T cells survive better
and undergo transient early activation and proliferation,
while prematurely exiting from the cell cycle [37]. To
address this hypothesis, we analysed the ability of T cells
in co-cultures to enter S-phase (synthesis phase) of the
cell cycle at 72 h upon exposure to a 5-h-long pulse with
5-ethynyl-2′-deoxyuridine (EdU).
We found a significant 38 % reduction of the fraction
of CD4+ T cells incorporating EdU in NSC/LNC co-
cultures [22.50 % (±0.4)] vs. control LNC [35.80 %
(±2.9); p ≤ 0.01] (Fig. 2). This effect became even more
striking in Th1 NSC/LNC and Th2 NSC/LNC, which
showed 56–61 % inhibition of the EdU uptake [Th1
NSC/LNC: 14.17 % (±3.3); Th2 NSC/LNC: 15.9 %
(±1.8); all p ≤ 0.001 vs. controls], thus confirming that
cytokine-induced NSC-reactive signals may hinder
optimal cell cycle progression in target T cells [8].
Together, these data confirm the ability of NSCs to
affect T cell activation and proliferation and suggest that
cytokine signalling (priming) on NSCs provides a higher
anti-proliferative effect.
Untargeted metabolomic studies identifies defective
arginine metabolism in Th1 NSCs
To investigate whether the exposure to a Th1-like cyto-
kine cocktail induced a metabolic alteration in NSCs,
which could interfere with the NSCs-T cell crosstalk, we
performed untargeted intracellular (endometabolome)
and extracellular (exometabolome) metabolomic profil-
ing of basal and Th1 NSCs. NSCs primed with Th2-like
cytokine cocktails (Th2 NSCs) were used as additional
controls. GC/MS and LC/MS in positive ion mode and
negative ion mode were performed according to the dif-
ferent metabolite ionization properties. In total, 215 and
86 metabolites were identified for the NSCs endo and
exo, when comparing basal, Th1 or Th2 NSCs. These
analytes spanned many classes of metabolites, including
amino acids, carbohydrates, peptides, lipids and nucleo-
tides (Additional file 3: Table S1).
Welch’s two-sample t tests were used to identify exo-
and endo-metabolites that differed significantly between
the experimental groups (Tables 1 and 2). On the one
hand, we found a total of 14 and 7 exo-metabolites that
were significantly upregulated in the conditioned media
of Th2 NSCs and Th1 NSCs, respectively, compared to
basal NSCs. On the other hand, we found a total of 2
and 1 exo-metabolites that were significantly downregu-
lated in the conditioned media of Th2 NSCs and Th1
NSCs, respectively, compared to basal NSCs (Table 1).
When we instead analysed the endometabolome of
NSCs, we found that Th1 NSCs had more pronounced
alterations with respect to Th2 NSCs and basal NSCs.
On the one hand, a total of 32 endo-metabolites were
significantly upregulated in Th1 NSCs (p ≤ 0.05 vs. basal
NSCs) compared to the only 9 endo-metabolites that
were significantly upregulated in Th2 NSCs. On the
other hand, 19 endo-metabolites were significantly
downregulated in Th1 NSCs (p ≤ 0.05 vs. basal NSCs)
compared to the only 4 endo-metabolites downregulated
in Th2 NSCs (Table 2).
Most importantly, partial least squares discriminant
analysis (PLS-DA) clearly segregated basal, Th1 or Th2
NSCs in separate clusters (Fig. 3a). Each condition clus-
tered separately, thus indicating that each NSC meta-
bolic profiles were highly specific. Out of the 215
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identified endo-metabolites, 61 were significantly differ-
ent between basal, Th1, and Th2 NSCs, as depicted in
the heatmap of the hierarchical clustering of the MS
peak intensities (Fig. 3b; p ≤ 0.05).
We then focused on the endometabolome, to investigate
the possible metabolic determinants of the enhanced
immune regulatory function of Th1 NSC on T cells. To
identify the intracellular metabolic pathways that were
mostly altered in Th1 NSCs (vs. basal NSCs), we
performed a metabolic pathway analysis (MetPA) on dif-
ferentially represented metabolites by using Metaboana-
lyst, a web-based tool for metabolomic data
interpretations [38]. This analysis identified multiple intra-
cellular metabolic pathways as being altered in Th1 NSCs
(vs. basal NSCs). Metabolites belonging to the metabolism
of arginine and proline, of phenylalanine and of tyrosine
and tryptophan were differentially enriched in Th1 NSCs
(vs. basal NSCs) (Fig. 4). In particular, when considering
Fig. 2 Cytokine-primed NSCs hinder cell cycle progression in LNC in vitro. Unfractionated LNC were co-cultured with NSC for 72 h as in Fig. 1.
EdU was added to the cells for the last 5 h of culture. Cells were then recovered, labelled with anti-CD4 mAb, stained for intracellular EdU
content, and analysed by flow cytometry. Events are depicted after gating on CD4+ T cells. Relative fractions of EdU+ cells are represented. Data
are expressed as mean EdU fold suppression (±SD) calculated by dividing the percent of EdU+CD44high cells over the control CD4+ T cells from
n≥ 3 independent experiments. Unpaired two-tailed t test for comparisons between groups were applied; **p≤ 0.01 and ***p≤ 0.001 vs. LNC; °
p≤ 0.05 and °°p ≤ 0.01 vs. NSCs/LNC
(See figure on previous page.)
Fig. 1 Cytokine-primed NSCs hinder lymph node cell (LNC) proliferation and cause premature CD44 downregulation. Unfractionated LNC
were labelled with the vital dye CFSE, cultured on CD3/CD28 coated mAb in the absence or the presence of NSCs, Th1 NSCs, or Th2
NSCs for 48 and 72 h in vitro. a Cells were surface stained with anti-CD4 and CD44 antibodies. Dot plots depict relative CD44 and CFSE
levels and are representative of gated CD4+ viable cells. b–d Absolute fractions of CFSEdim (b), CFSEdimCD44low (c), and CFSEdimCD44high
CD4+ T cells are shown (d). Data in b–d are expressed as mean % (±SD) and have been collected out of n ≥ 3 independent experiments.
e Representative dot plots of relative CFSE and TO-PRO3 levels after gating on CD4+ T cells as in a–d. Unpaired two-tailed t test for
comparisons between groups were applied; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs. LNC
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the log p value, differences in the arginine and proline me-
tabolism of Th1 NSCs were the most significant when
compared to basal NSCs (Additional file 4: Table S2). Ac-
cordingly, the arginine downstream metabolites agmatine,
N-acetylputrescine and 4-guanidinobutanoate—which are
all members of the arginine decarboxylase pathway—were
significantly upregulated in Th1 NSCs (p ≤ 0.01 and p ≤
0.05 vs. basal and Th2 NSCs) (Fig. 5).
Untargeted metabolomics can therefore be efficiently
used to identify several differences in the endo- and exo-
metabolome of primed NSCs. In particular, we found
that arginine and proline are the most differentially
regulated in the endometabolome of Th1 NSCs.
Targeted metabolomics identifies defective arginase
activity within the urea cycle in Th1 NSCs
Arginine levels have been reported to be critical for T cell
activation and proliferation [39]. Therefore, we decided to
focus on the intracellular arginine metabolism to clarify
which metabolic routes were specifically altered in Th1
NSCs. The cells were incubated with uniformly labelled
U-13C6 L-arginine in the absence or in the presence of
Th1 and Th2 cytokines and isotopologues distribution of
arginine and downstream metabolites was assessed by LC/
MS (Fig. 6). Within 2 h, the amount of labelled intracellu-
lar arginine (m + 6) was significantly lower in Th1 NSCs
(p ≤ 0.01), when compared to both basal and Th2 NSCs
(Fig. 6a). In addition, labelled ornithine (m + 5) was
undetectable in Th1 NSCs by 2 h (Fig. 6b), and overall
levels of unlabelled ornithine (m + 0) were lower in these
cells (p ≤ 0.05). By 16 h, differences in the arginine and
ornithine intracellular levels between basal NSCs and Th1
NSCs were no longer statistically significant.
The reduced amount of m + 6 arginine (Fig. 6a) and
m + 5 ornithine (Fig. 6b), together with lower unlabelled
m + 0 intracellular ornithine, supported a deregulation of
arginine metabolism within the urea cycle in Th1 NSCs
(Fig. 6e). Since arginase is the urea cycle enzyme involved
in the conversion of arginine to ornithine and urea
(Fig. 6e), we hypothesized that the observed metabolic
changes were depending on the defects of arginase activ-
ity. To verify this hypothesis, we measured the arginase
enzymatic activity in cell extracts and assessed urea
production by a colorimetric assay. Th1 NSCs showed a
significant decrease in the arginase activity (Fig. 6c) and in
the rate of urea production, compared to basal and Th2
NSCs (p ≤ 0.05 and p ≤ 0.01) (Fig. 6d).
Altogether, these findings suggest that inflammatory
cytokine signalling causes a selective defect of arginase
activity in Th1 NSCs.
Expression of different arginase isoforms in NSCs
To further understand the regulation of arginase in
cytokine-primed NSCs, we first investigated the expression
of inducible (type I) and constitutive (type II) arginases in
NSCs in vitro. We used immunofluorescence staining of
Mito-DsRed-transduced Nestin+ NSCs to quantify the
subcellular localization of cytosolic (type I) and mitochon-
drial (type II) arginase isoforms. We observed low basal
expression of both arginases in NSCs and found that NSCs
primed with Th1 cytokines had a significantly downregu-
lated expression of arginase II, coupled with a significantly
increased expression of arginase I (Fig. 7a).
As confirmation of these in vitro data, we interrogated
a more physiological inflammatory context to examine
the expression of both arginases by NSCs in vivo within
brain germinal niches [40]. In mice with myelin
oligodendrocyte glycoprotein (MOG)-induced experimental
autoimmune encephalomyelitis (EAE), as model of Th1-
like antigen-specific chronic inflammatory disease of the
central nervous system [41], we found a downregulation of
arginase II and concomitant upregulation of arginase I in
Table 2 Summary table for untargeted endo and exo-metabolomic NSC profiling: NSC endometabolome
Welch’s two-sample t tests were used to identify metabolites that are significantly regulated between experimental groups within cells (Table 1) or in the media
(Table 2) (upregulated metabolites are in red whereas downregulated metabolites are in green)
Table 1 Summary table for untargeted endo and exo-metabolomic NSC profiling: NSC exometabolome
Welch’s two-sample t tests were used to identify metabolites that are significantly regulated between experimental groups within cells (Table 1) or in the media
(Table 2) (up regulated metabolites are in red whereas downregulated metabolites are in green)
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Nestin+ NSCs of the SVZ at both 25 and 50 days after
immunization vs. healthy controls (Fig. 7b).
These findings suggest that the previously observed
decrease in the intracellular arginase activity in Th1
NSCs might well be ascribed to an imbalance between
decreased arginase II expression (e.g. controlled at the
post-translational level) and increased arginase I.
We then reasoned that (i) a shift in arginine metabol-
ism and (ii) subsequent secretion of active arginases
might be driving some of the immune modulatory prop-
erties of cytokine-primed NSCs.
To address the latter of these outstanding questions,
we performed western blot analysis for both arginase I
and II in NSC-conditioned media and found evidence of
secreted arginase I, but not of arginase II (Fig. 7c). The
secretion of arginase I might be an active secretion
process by NSCs, instead of being a bystander effect of
NSC death, as suggested by the comparable viability of
basal, Th1 and Th2 NSCs (Additional file 5: Figure S3).
Extracellular arginase I drives NSC modulation of T cell
responses
To address the role of extracellular arginases in the im-
mune modulatory effects of Th1 NSCs, we co-cultured
basal, Th1, and Th2 NSCs with LNCs in the absence or
in the presence of the potent, reversible, pan-arginase
inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) and
measured EdU incorporation after 72 h in vitro.
Co-cultures with NSCs induced significant 40 % reduc-
tion of the fraction of CD44highEdU+ CD4+ T cells vs. LNCs
(p ≤ 0.01). This effect was more striking in co-cultures with
Th1 and Th2 NSCs, respectively (58 and 52 % reduction;
p ≤ 0.01 or p ≤ 0.05 vs. NSC/LNC and p ≤ 0.001 vs. LNC).
Pan-arginase inhibition by nor-NOHA had no effects on
(See figure on previous page.)
Fig. 3 Untargeted metabolomics analysis of NSCs under Th1- and Th2-like cytokines: Multivariate analysis (PLS-DA) and hierarchical clustering. a PLS-DA
score assessing the clustering of the three sample groups (basal NSCs (group 0), Th1 NSCs (group 1), or Th2 NSCs (group 2)) was performed on significant
metabolites by using MetaboAnalyst 2.0 software. b Hierarchical clustering heatmap for MS peak intensities of significantly (p≤ 0.05) different intracellular
metabolites among basal NSCs, Th1 NSCs, or Th2 NSCs. MultiExperiment Viewer software (MeV) (v 4.6.2) was applied on NSCs significant endometabolome
dataset with Pearson correlation metric. Sixty-one intracellular metabolites were significantly different in the three experimental conditions among 215
identified metabolites by LC-MS/MS and GC-MS/MS
Fig. 4 Metabolic pathways analysis of Th1 NSCs. Enriched metabolic pathways were ranked according to their FDR values calculated by the
MetPa method implemented in MetaboAnalyst 2.0 software. The most significant pathways for Th1 NSCs compared to basal NSCs were
represented by both the bigger/red dots and by those dots with higher log p value. The pathway impact is calculated as the sum of the
importance measures of the matched metabolites normalized by the sum of the importance measures of all metabolites in each pathway
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NSC/LNC but induced a 13 % rescue of the anti-
proliferative properties of Th1 NSCs (p ≤ 0.01 vs. NSC/
LNC+ nor-NOHA) and a further 1.8-fold lower rescue of
the anti-proliferative effects in Th2 NSC/LNC (p ≤ 0.05 vs.
Th1 NSC/LNC+ nor-NOHA) (Fig. 7d, e).
The fact that cytokine-primed NSCs were still in part
capable to inhibit T cells proliferation in the presence of
pan-arginase inhibition suggests that mechanisms other
than extracellular arginase I or II contribute to the broad
NSCs immune regulatory activities, as described
elsewhere [3].
Overall, our findings suggest that deregulation of the
arginine pathway and the release of arginase I contribute
to part of the NSCs immune regulatory activities,
especially in the case of NSCs primed with extracellular
inflammatory signals.
Discussion
Recent studies revealed that NSCs secrete neuroprotec-
tive and immune regulatory molecules able to mediate a
cross talk with the surrounding tissues after transplant-
ation and provide significant modulation of immune re-
sponses both in vitro and in vivo [16, 42]. While no final
mechanisms or direct evidence of stem cell-to-immune
system interaction is yet available, a number of studies
are now focussing on the cellular signalling between
grafted stem cells and endogenous target cells, with the
aim of clarifying its physiological or circumstantial na-
ture, and elucidating its molecular signature and thera-
peutic potential [15, 43, 44]. Whether and how cytokines
produced in the CNS inflammatory or ischaemic envir-
onment in vivo modulate the NSCs immune regulatory
activity is not unravelled yet but represents an intriguing
possibility in developing more effective NSC-based
therapeutic approaches [16]. Therefore, we reasoned that
combined metabolomics-metabolic flux studies could
provide useful insights into the NSC-immune cells
crosstalk [45] elucidating the role of cytokines stimula-
tion in the NSC metabolic reprogramming.
Previous evidence revealed that preconditioning (priming)
of human NSCs by pro-inflammatory cytokines increased
their cytotoxic activity towards human monocytic and
lymphocytic cell lines via a TNF-α-mediated mechanism
[14]. Here, we confirmed the existence of a crosstalk be-
tween NSCs and LNC/T cells, which is suggested by a pre-
mature downregulation of the activation marker CD44 on T
cells and the failure of LNC to progress through the cell
cycle and to proliferate. We also found that exposing NSCs
to inflammatory Th1-like or Th2-like cytokines augmented
the innate NSCs ability to repress T cells proliferation.
In the attempt to find a metabolic hypothesis for the
reduced Tcell proliferation promoted by Th1 or Th2 NSCs,
we performed untargeted metabolomics by LC-MS/MS
and GC-MS/MS, which covered a wide panel of both
intracellular and extracellular metabolites belonging to the
most important biochemical pathways. By high-throughput
metabolomics, we found an alteration of intracellular
arginine metabolism in NSCs, which was especially evident
in Th1 NSCs and well correlated with the NSC anti-
proliferative effect on T cells. We observed that the metab-
olism of arginine and proline was the most significant
Fig. 5 Th1-like cytokines affect NSC arginine metabolism altering the
levels of arginine-derived polyamines. Box plot of NSCs endo-metabolites
for the arginine pathway detected by LC-MS/MS expressed as mean
of MS peak intensity for five independent experiments. Agmatine (a),
N-acetylputrescine (b), and 4-guanidinobutanoate (c) levels were
upregulated in Th1 NSCs compared to basal NSCs. Unpaired
two-tailed t test for comparisons between groups were applied.
*p ≤ 0.05 and **p ≤ 0.01 vs. basal NSCs, ^p ≤ 0.05 vs. Th2 NSCs
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altered pathway for Th1 NSCs. This was supported by a
significant decrease of arginase enzymatic activity and urea
production as well as by the upregulation of other intracel-
lular downstream arginine metabolites such as agmatine,
N-acetylputrescine and 4-guanidinobutanoate.
Relative metabolite concentration changes are not
sufficient to infer directionality of metabolic rates
(fluxes) [46]. Thus, to investigate and validate changes in
arginine metabolism, we incubated cells with U-13C6 L-
arginine. This analysis confirmed the arginine pathway
as the most relevant biochemical system affected by
Th1-like (but not Th2-like) cytokines. The upregulation
of arginine downstream metabolites such as agmatine,
N-acetylputrescine and 4-guanidinobutanoate shown by
untargeted metabolomics might mirror the significantly
decreased amount of intracellular arginine—as such be-
ing predictive of faster arginine turnover—in Th1 NSCs.
Changes in intracellular metabolic fluxes were best
Fig. 6 Th1-like cytokines affect NSC arginine metabolism by inducing defective arginase activity within the urea cycle. a NSCs were cultured
in complete medium supplemented with U-13C6 L-arginine for 2 and 16 h in the absence and in the presence of Th1- or Th2-like cytokines.
Metabolic flux analysis was performed by measuring all labelled metabolites derived from arginine by LC/MS [labelled arginine (a) and ornithine
(b) herein reported]. c Arginase enzymatic activity in basal NSCs as well as Th1 and Th2 NSCs was detected by arginase activity colorimetric assay
kit. d NSC urea levels were detected by colorimetric assay measuring the ability of NSCs to convert arginine into urea in basal condition and
under Th1 or Th2 treatment. e Schematic representation of the most significant findings for the metabolic alteration in the NSC arginine
metabolism (modified from [59]). *p≤ 0.05 or **p≤ 0.01 vs. basal and Th2 NSCs
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detected within 2 h of cytokine stimulation, while NSC
inhibitory activities in NSCs/T cell co-cultures were
observed at later times (48–72 h). We speculate the
former changes to occur early after cytokine stimulation,
while the latter ones to be better observed at later times
as possibly caused by transcriptional or translational
events controlled by changes in NPCs metabolic fluxes.
Arginase catalyzes the conversion of arginine to orni-
thine and urea [47]. While arginase II is constitutively
expressed as the principal isoform in the nervous system
and is localized in the mitochondria [48], arginase I is
normally not expressed but induced in the cytosol. Argi-
nase I expression in myeloid-derived suppressor cells
(MDSCs) mediated their immunosuppressive activity in
cancer patients [49] by depleting arginine in the tumour
microenvironment and subsequently inhibiting T cell
proliferation [49–51]. Arginase I secretion by mature
myeloid cells in the tumour microenvironment inhibits
antigen-specific T cell responses [52]. Likewise, overex-
pression of the extracellular arginase I contribute to the
anti-inflammatory phenotype of phosphatase and tensin
homolog (PTEN)-deficient myeloid cells [53].
We found that in vitro NSCs constitutively express
arginase I, upregulate its expression upon priming with
Th1 or Th2 cytokines and secrete it in tissue culture
media. This is not surprising, as arginase I is not highly
expressed in the healthy CNS [40, 54], but it is instead
significantly upregulated in inflammatory conditions. As a
matter of fact, sustained enhancement of arginase I
expression has been well described during EAE within the
spinal cord of both mice and rats [55]. However, this
increase has been related so far to the prevailing M2
phenotype of local mononuclear phagocytes rather than
being intrinsic to the CNS parenchyma [56]. Our findings
suggest that arginase I is indeed upregulated in Nestin+
NSCs of the SVZ at both 25 and 50 dpi in EAE mice.
We also found that in vitro NSCs constitutively express
arginase II and its expression is reduced by Th1 cytokines
in vitro (while Th2 cytokines have no effect). Accordingly,
in our in vivo settings, we found that arginase II is
downregulated in the SVZ of EAE mice at chronic time
points (i.e. 25 and 50 dpi). This is in line with previous
data showing that arginase II gene expression rises in the
spinal cord of EAE mice at the peak of disease, but it soon
falls to levels below the baseline during recovery [57].
To understand whether changes in arginase activity in
NSCs could be involved in their immune modulatory
properties, we treated NSCs with the pan-arginase inhibi-
tor nor-NOHA. We found that nor-NOHA had no effects
on NSC/T cells but induced significant rescue of the anti-
proliferative effects especially for Th1 NSCs in co-cultures
with T cells in vitro. In the presence of nor-NOHA, Th1
NSCs—and to a 1.8-fold lower extent Th2 NSCs—no
longer differed from control NSCs, thus suggesting that
arginase inhibition partially rescues the anti-proliferative
effects of NSCs. As arginase I—but not arginase II—was
mainly present in the extracellular compartment, we
speculated that nor-NOHA could mostly inhibit extracel-
lular arginase I function in NSC/LNC co-cultures.
However, we cannot exclude that this pan-arginase
inhibitor could also have an effect on the intracellular
arginase II and therefore the observed rescue of the anti-
proliferative activity observed for both Th1 and Th2
NSC/LNC may well be the sum of both the effects of
the arginase inhibitor on intracellular arginase II and
extracellular arginase I, as described [58].
We therefore hypothesized that defective intracellular
arginase activity in cytokine-primed NSCs induces a
rearrangement of intracellular arginine pool and that
this effect together with the secretion of arginase I might
reduce the pool of extracellular arginine, needed for
proper T cell expansion.
Consistent with this hypothesis, we showed that the
arginase I NSCs secretion could be partly responsible for
the immune suppressive effects especially when NSCs
sense the inflammatory environment (e.g., via cytokine
receptors) [15].
The finding that nor-NOHA only partially rescued the
anti-proliferative activity of cytokine-primed NSCs
suggests that targeting the arginase activity in NSCs
(See figure on previous page.)
Fig. 7 Cytokine-primed NSCs hinder LNC proliferation via a mechanism that is partly dependent on secreted arginase I. a Cytosolic arginase I
(green) expression in Nestin (white) immunoreactive NSCs is increased upon priming with Th1 and Th2 cytokines (arrowheads). Arginase II (green)
co-localizes mostly with red mitochondria (arrows), and it is reduced by priming with Th1 cytokines only. Mitochondria are in red, while nuclei are
counterstained with DAPI (blue). Data are expressed as mean intensity (±SD) over total DAPI and have been collected out of n ≥ 3 independent
experiments. *p≤ 0.05 and **p≤ 0.01 vs. basal NSCs. Scale bars 40 μm. b After EAE (25 and 50 days post immunization—dpi), arginase I expression
is increased in Nestin+ SVZ-resident NSCs (red), compared to healthy controls (left panels). On the contrary, arginase II expression by Nestin+ SVZ-
resident NSCs (red) is reduced in EAE mice compared to healthy controls (right panels). CD45-positive leukocytes are showed in white; nuclei are
counterstained with DAPI (blue). Scale bars 50 μm. c Arginase I and arginase II protein expression in NSC supernatants detected by western
blotting. Western blot analyses were performed starting from the same protein quantity (100 μg of total protein). This panel is representative of
n≥ 3 independent experiments. d Representative dot plots of EdU+CD44high CD4+ T cells. e Relative fraction of proliferating EdU+ cells within
CD44highCD4+ viable T cells. Data are expressed as mean EdU fold suppression (±SD) calculated dividing the percent of EdU+ cells in experimental
samples over controls from n≥ 3 independent experiments. Unpaired two-tailed t-test for comparisons between groups were applied; **p ≤ 0.01
and ***p≤ 0.001 vs. LNC; °p≤ 0.05 and °°p ≤ 0.01 vs. NSC/LNC
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could provide a new way of interfering with NSCs
function in vivo and that mechanisms other than extra-
cellular arginase I would contribute to the broad NSCs
immune regulatory activities [3].
Conclusions
In conclusion, our work validates the use of metabolic
profiling as a hypothesis-generating tool to unravel how
stem cell-mediated mechanisms of tissue restoration are
affected by local inflammatory responses and identifies
arginase signalling as novel mechanism of adaptive NSC-
to-immune system communication. While further studies
are required to establish the absolute relevance of the
NSC arginase-dependent immune modulatory mechan-
ism, targeting arginase activity in NSCs could provide a
new way of enhancing therapeutic immune-regulation.
Besides guiding our hypothesis on NSC immune-
regulation on arginine pathway, this metabolomics
approach offers a more broad and global profiling of NSCs
under cytokines stimulation with other interesting path-
ways affected by Th1 pro-inflammatory cytokines that in-
clude phenylalanine, tyrosine and tryptophan metabolism,
which are still under intense investigation. The very same
technology might also be useful to investigate whether the
crosstalk between NSCs and T cells occurs in a bi-
directional way and if T cells alter the NSCs secretome.
Finally, we foresee that this high-throughput omic
approach applied to the study of the NSCs phenotype
might also provide promising therapeutic perspectives
for inflammatory diseases where metabolic rearrange-
ment plays a key role in disease progression.
Additional files
Additional file 1: Figure S1. NSCs induce downregulation of the
activation cell surface marker CD44 on purified CD4+ T cells. CD4+ T cells
were purified by negative selection from total LNC, labelled with the vital
dye CFSE, and cultured on CD3/CD28 coated mAb in the absence or the
presence of NSCs, Th1 NSCs or Th2 NSCs for 72 h. Cells were surface stained
with anti-CD4 and CD44 antibodies. Absolute fractions of CFSEdimCD44low
CD4+ T cells are depicted. Data are expressed as mean % (±SD) from n≥ 3
independent experiments. *p≤ 0.05 and **p≤ 0.01 vs. T cells.
Additional file 2: Figure S2. NSCs reduce LNC death in NSC/LNC
co-cultures. LNC were labelled with the vital dye CFSE, cultured on CD3/CD28
coated mAb in the absence or the presence of NSCs, Th1 NSCs or Th2 NSCs
for 72 h. Cells were surface stained with anti-CD4, and TO-PRO3 Iodide was
added before flow cytometry analysis to identify dead cells. Data represent
absolute fractions of TO-PRO3+ CD4+ cells and are expressed as mean % (±SD)
from n≥ 3 independent experiments. **p≤ 0.01 and ***p≤ 0.001 vs. LNC.
Additional file 3: Table S1. NSC endometabolome (a) and
exometabolome (b) detected by LC-MS/MS or GC-MS/MS. The
endometabolome and exometabolome dataset comprise a total of
215 and 86 metabolites, respectively. Following log transformation
and imputation with minimum observed values for each compound,
Welch’s two-sample t tests were used to identify metabolites that
differed significantly between experimental groups. A summary of
the numbers of metabolites that achieved statistical significance
(p≤ 0.05), as well as those approaching significance (0.05≤ p≤ 0.1),
is reported. An estimate of the false discovery rate (q value) is calculated to
take into account the multiple comparisons that normally occur in
metabolomic-based studies.
Additional file 4: Table S2. Metabolic pathways analysis of Th1 NSCs.
This table is representative of the most significant pathways for Th1 NSCs
compared to basal NSCs matched according to p values from pathway
enrichment analysis and pathway impact values reported in Fig. 4.
Additional file 5: Figure S3. Co-culturing with LNC and cytokine
priming has no effects on NSC survival. LNC were labelled with the vital
dye CFSE and co-cultured with NSC, Th1 NSCs or Th2 NSCs for 72 h as in
Additional file 2: Fig. S2. Absolute fractions of CFSE− TO-PRO3+ CD4− cells,
as an indicator of dead NSCs are expressed as mean % (±SD) from n ≥ 3
independent experiments.
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